drugset / Trial / NCT03578822
Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized,controlled, double-blinded, phase 3 clinical study to evaluate the efficacy and safety of recombinant human urokinase(rhPro-UK) versus basic treatment for patients with acute ischaemic stroke in 4.5-6 hours after stroke onset.
Timeline
- Start
- 2018-08-10
- Primary completion
- 2020-02-28
- Completion
- 2020-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 300 mg | Oral |
| Subject | rhPro-UK | Protein / enzyme biologic | 35 mg | Other |